Look Under The Hood: RWL Has 13% Upside

Analysts project a 12.86% upside for the Invesco S&P 500 Revenue ETF (RWL), with an implied target price of $113.11 based on the average analyst targets of its underlying holdings, compared to its recent trading price of $100.22. Newmont Corp (NEM), Assurant Inc (AIZ), and Charles River Laboratories International Inc. (CRL) are three of RWL's holdings with the most notable upside, with analyst target upsides of 18.18%, 17.71%, and 16.43% respectively; however, investors should conduct further research to determine if these targets are justified given recent company and industry developments.

Analysis

The Invesco S&P 500 Revenue ETF (RWL) exhibits an implied analyst target price of $113.11 per unit, suggesting a 12.86% potential upside from its recent trading price of $100.22, based on the weighted average analyst targets of its underlying holdings. Among its constituents, Newmont Corp (NEM), Assurant Inc (AIZ), and Charles River Laboratories International Inc. (CRL) show notable potential, with average analyst targets indicating upsides of 18.18% (to $62.46 for NEM), 17.71% (to $233.00 for AIZ), and 16.43% (to $158.64 for CRL) respectively from their recent prices. Despite this positive outlook from analyst consensus for these specific securities, the information carries a cautious undertone, emphasizing that investors must conduct further research to ascertain if these targets are justified or potentially overly optimistic, particularly considering recent company and industry developments. This cautious stance aligns with the provided mixed general sentiment score (0.15), suggesting that while specific targets are bullish, a broader validation is warranted.

Key Decisions for Investors

• Investors should note the 12.86% implied upside for the Invesco S&P 500 Revenue ETF (RWL) and the significant potential upsides for its holdings Newmont Corp (NEM), Assurant Inc (AIZ), and Charles River Laboratories (CRL) based on current average analyst target prices.